Skip to content
Subscriber Only

Purdue’s Sacklers Boost Opioid Settlement Offer Up to $6 Billion

  • Proposal is at least $1 billion more than earlier blocked deal
  • No final agreement has been reached, mediator says in report
Purdue Pharma OxyContin

Purdue Pharma OxyContin

Photographer: George Frey/Bloomberg

Updated on

Members of the billionaire Sackler family that own Purdue Pharma LP have offered to pay as much as $6 billion to revive the OxyContin maker’s imperiled opioid settlement, a more-than $1 billion increase from their existing proposal.

The new settlement offer would see the Sackler family pay at least $5.5 billion, with additional money contingent on certain asset sales, a court appointed mediator, U.S. Bankruptcy Judge Shelley Chapman, said in a report Friday. A final deal hasn’t been reached, according to the mediator.